Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 125 results
A minimalist illustration of a cancer cell with a diagnostic test overlay in a dark palette.

Jun 23, 2026

Qlucore Receives EUR 0.5 Million EU Payment

Qlucore has successfully secured a third payment of approximately EUR 0.5 million as part of a larger EUR 2.5 million EU grant aimed at advancing cancer diagnostic solutions.The funding is intended to enhance the development of clinical diagnostics specifically for acute myeloid leukemia (AML) and bladder cancer. This initiative reflects a growing commitment to precision medicine, leveraging AI-driven software to improve diagnostic accuracy and healthcare efficiency.Qlucore's advancements includ
A liquid biopsy sample in a test tube on a laboratory countertop during blue hour.

Jun 22, 2026

Is Twist Bioscience’s (TWST) New ATM Program Quietly Reframing Its AI Genomics Investment Story?

Twist Bioscience is making strategic moves to enhance its investment narrative through a new financing program aimed at bolstering its role in AI-driven genomics.In June 2026, Twist Bioscience initiated an extensive shelf registration that includes a $200 million at-the-market equity offering. This move not only provides the company with increased financial flexibility but also positions it prominently in the liquid biopsy and AI genomics sectors. The interest from Osterweis Opportunity Fund fur
A flat illustration of a blood cell representing cancer diagnostics.

Jun 17, 2026

Qlucore Receives Approval for EUR 0.5 Million EU Payment

Qlucore has secured a third installment of approximately EUR 0.5 million from a total EU grant of EUR 2.5 million, aimed at enhancing cancer diagnostic solutions.The funding is part of a three-year initiative focused on developing clinical diagnostic software for acute myeloid leukemia (AML) and bladder cancer. With the recent approval, Qlucore is set to continue its progress in creating CE-marked software intended for clinical laboratories, which will also aid in developing companion diagnostic
A minimalist illustration of a blood droplet and heart silhouette on a dark background.

Jun 15, 2026

Cardio Diagnostics Leverages AI and Genetics to Transform Cardiovascular Risk Detection

Cardio Diagnostics Holdings is advancing cardiovascular disease detection by integrating AI with genetic and epigenetic biomarkers, aiming for more effective early risk identification and personalized interventions.The company is developing a range of solutions that utilize artificial intelligence alongside genetic and epigenetic data to enhance the prevention, detection, and management of cardiovascular diseases. Their platform focuses on providing personalized insights through blood-based test
A blood sample and microscope in a dimly lit lab setting

Jun 15, 2026

Cardio Diagnostics (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection

Cardio Diagnostics Holdings is leveraging AI and genetic insights to enhance cardiovascular risk assessment and management.The growing demand for advanced tools to detect cardiovascular disease risk earlier is being met by Cardio Diagnostics Holdings (NASDAQ: CDIO). The company is developing innovative solutions that integrate artificial intelligence with genetic and epigenetic data to offer personalized insights. Their platform utilizes blood-based testing to analyze biomarkers, aiming to trans
Flat illustration of a DNA strand and epigenetic marker

Jun 15, 2026

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Nano Dimension has announced a strategic partnership with Infinite Epigenetics, aimed at creating a publicly traded company focused on AI-driven preventive health and diagnostics. This collaboration follows a comprehensive review of potential opportunities in the healthcare sector, ultimately identifying Infinite Epigenetics as the most promising candidate for long-term value creation.The proposed merger will leverage Nano Dimension's financial resources and Nasdaq listing to tap into the burgeo
A minimalist illustration of an ECG waveform and DNA helix on a solid background.

Jun 13, 2026

New FDA Clearances for Genomics and Cardiac AI Could Be A Game Changer For Tempus AI (TEM)

Tempus AI has recently achieved significant FDA approvals that could enhance its position in the precision medicine landscape. The company received clearance for its xT CDx sequencing platform focused on tumor-only indications and published a validation study for its ECG-AF software, which predicts the risk of atrial fibrillation or flutter over the next year.These developments highlight Tempus AI's strategy to integrate extensive genomic data with AI technologies, aiming to improve decision-mak
A minimalist representation of a genome and a cell in a dark palette.

Jun 11, 2026

Infosys-backed 4baseCare Raises INR 128 Cr to Advance Oncology Platform Globally

4baseCare, a precision oncology startup backed by Infosys, has successfully raised INR 128 crore in Series B funding to enhance its global oncology platform, OncoTwin. This investment aims to expand its genomics laboratory network and improve access to precision oncology, particularly for underrepresented populations in various regions.The funding round included a significant top-up of INR 38 crore led by growX Ventures and Infosys, with contributions from existing investors. This capital will e
A minimalist illustration of a DNA strand and data points representing precision oncology.

Jun 10, 2026

Sophia Genetics, Memorial Sloan Kettering Sign Strategic Collaboration for AI-Powered Precision Oncology Hub

Memorial Sloan Kettering Cancer Center and Sophia Genetics have announced a strategic collaboration to create an AI-powered precision oncology hub aimed at enhancing cancer care through advanced analytics and clinical expertise.The partnership will leverage Memorial Sloan Kettering's extensive clinical datasets and expertise along with Sophia Genetics' AI-driven analytics platform. This initiative seeks to establish a global hub for precision medicine, integrating the strengths of both organizat
A blood sample in a test tube on a lab bench

Jun 9, 2026

Machine Learning Model Enhances Precision of Liquid Biopsy Diagnostics

Researchers at Johns Hopkins Kimmel Cancer Center have developed a groundbreaking machine learning model named plasmaCHORD, aimed at enhancing the accuracy of mutation identification in liquid biopsies for cancer diagnostics. This innovative tool significantly improves the clinical decision-making process by effectively distinguishing between cancer-derived mutations and those from other biological processes, which is crucial for targeted therapeutic interventions.Liquid biopsies have revolution
A minimalist representation of a mass spectrometer and a molecule in a dark color scheme.

Jun 8, 2026

Did New Orbitrap and AI Proteomics Launches Just Reframe Thermo Fisher Scientific's (TMO) Tools Integration Story?

Thermo Fisher Scientific has introduced its new Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, showcasing advancements in multiomics and AI-enabled proteomics at the recent American Society for Mass Spectrometry Conference. These innovations aim to enhance the detection of low-abundance molecules, thereby supporting complex biopharmaceutical research and regulatory compliance.The launches are significant as they reinforce Thermo Fisher's strategy to bridge early biological disco
A blood sample in a vial on a lab bench with a microscope behind it.

Jun 8, 2026

Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences

Strand Life Sciences is positioning itself to integrate genomics into everyday healthcare, aiming to make genomic insights as commonplace as traditional monitoring tools like blood pressure monitors. In a recent interview, CEO Dr. Ramesh Hariharan discussed the company's strategic evolution in precision medicine, diagnostics, and consumer genomics.As precision medicine gains traction in India, Strand Life Sciences is expanding its focus from enterprise bioinformatics to include diagnostics and p